# DESCRIPTION

## FIELD OF INVENTION

- relate to method

## BACKGROUND OF INVENTION

- introduce breast cancer
- classify breast cancer
- limitations of treatments

## SUMMARY OF INVENTION

- introduce method
- embodiment of method

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

- define "comprising"
- introduce protein kinase C (PKC) as a target agent for TNBC treatment
- describe the role of PKC in various disease processes
- discuss the inverse relationship between ER and PKC activity and abundance
- describe the elevation of PKC in malignant versus normal breast tissue
- associate PRKCA with antiestrogen resistance and tumor aggressiveness
- identify PRKCA as a central signaling node and therapeutic target for breast cancer stem cells
- imply PKC as a potential specific therapeutic target agent for TNBC
- introduce chelerythrine as a specific PKC inhibitor
- describe the anti-cancer effect of chelerythrine against TNBC cell lines
- outline materials and methods
- list reagents and antibodies used
- describe cell culture conditions
- outline in vitro cell proliferation assay (SRB assay)
- describe colony formation assay
- outline flow-cytometric analysis of cell cycle
- outline flow-cytometric analysis of apoptosis
- describe assessment of cell morphological changes
- outline retrieval of gene expression data from CCLE database
- describe quantitative real-time PCR
- outline Western blotting
- describe dual-drug combination assay
- introduce results
- describe chelerythrine's selective inhibition of proliferation of TNBC cell lines
- show IC50 values of chelerythrine on TNBC and non-TNBC cell lines
- describe time-dependent inhibition of cell growth by chelerythrine
- confirm selective anti-proliferative activity of chelerythrine by colony formation assay
- describe chelerythrine's differential induction of cell cycle arrest in TNBC cell lines
- show cell cycle distribution of TNBC and non-TNBC cell lines after chelerythrine treatment
- describe chelerythrine's selective induction of apoptosis in TNBC cell lines
- show morphological characteristics of apoptosis in TNBC cells
- detect cleaved nuclear poly (ADP-ribose) polymerase (cPARP) in TNBC cell lines
- quantify apoptotic cell fractions by flow cytometry
- describe time-dependent induction of apoptosis by chelerythrine
- discuss multiple PKC isozymes mediating the selective inhibitory activity of chelerythrine
- measure mRNA expression level of PRKCA in breast cancer cell lines
- confirm protein expression level of PRKCA by western blotting
- identify PKN1 and PKN2 as PKC subtypes overexpressed in TNBC cell lines
- analyze mRNA expression levels of PKN1 and PKN2 in breast cancer cell lines
- identify PRKCD, PRKCH, and PRKCZ as PKC isozymes less expressed in TNBC cells
- describe chelerythrine's enhancement of chemotherapy activity
- discuss the potential of chelerythrine as a promising regimen for TNBC tumors

